

University of Massachusetts Medical School

eScholarship@UMMS

UMass Center for Clinical and Translational
Science Research Retreat

2014 UMass Center for Clinical and
Translational Science Research Retreat

May 20th, 12:30 PM

In Vivo Evaluation of a Biomimetic Polymer-Doxorubicin Conjugate for Cancer Therapy

Matthew Skinner

University of Massachusetts Amherst

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat



Part of the [Medicinal-Pharmaceutical Chemistry Commons](#), [Neoplasms Commons](#), [Polymer Chemistry Commons](#), [Therapeutics Commons](#), and the [Translational Medical Research Commons](#)

Skinner M, Page SM, Chen X, Parelkar SS, Wong K, Mora M, Schneider SS, Emrick TS. (2014). In Vivo Evaluation of a Biomimetic Polymer-Doxorubicin Conjugate for Cancer Therapy. UMass Center for Clinical and Translational Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2014/posters/115

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](#).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

In Vivo Evaluation of a Biomimetic Polymer-Doxorubicin Conjugate for Cancer Therapy

Matthew Skinner,¹ Samantha McRae Page,¹ Xiangji Chen,¹ Sangram S. Parekar,¹
Kaitlyn Wong,² Maria Mora,² Sallie Schneider,² and Todd Emrick^{1,*}

¹*Polymer Science & Engineering Department, University of Massachusetts
120 Governors Drive, Amherst, MA 01003*

²*Pioneer Valley Life Sciences Institute
3601 Main Street, Springfield, MA 01199*

Corresponding Author

*tsemrick@mail.pse.umass.edu

Abstract

This poster will describe a novel polymer pro-drug platform designed for conjugation and delivery of chemotherapeutics. Specifically, polymer pro-drugs were prepared from functional polymer zwitterions and doxorubicin (DOX), and evaluated *in vivo* to assess toxicological, pharmacokinetic and therapeutic properties. The biocompatible polymer scaffold (PolyMPC) consists of zwitterionic phosphorylcholine pendent groups, which mimic the natural hydrophilic moieties of phospholipids in cell membranes, and hydrazone linkages that allow for pH-triggered release of DOX. PolyMPC-DOX pro-drugs were isolated as dry solids using a facile strategy that allows for precise control of molecular weight and DOX incorporation. *In vivo* toxicity of PolyMPC and PolyMPC-DOX was assessed in a murine model. The maximum tolerated dose of the pro-drug was five times greater than that of free DOX, while PolyMPC alone exhibited no toxicity even at a dose of 800 mg/kg. A pharmacokinetic study in tumor-bearing mice demonstrated a significant increase in circulation half-life of conjugated DOX ($t_{1/2}$ =2 hours) compared to free DOX ($t_{1/2}$ =15 minutes), with conjugated DOX detectable in blood serum for longer than 24 hours. This pronounced enhancement in circulation time was attributed to the macromolecular scaffold, which precludes rapid renal clearance compared to native DOX. Examination of mice given PolyMPC-DOX five days after injection in the PK study showed a three-fold increase of drug accumulated in tumor tissue compared to that of mice treated with free DOX and drug accumulation in off-target organs was reduced for mice given DOX conjugate. The therapeutic efficacy of the PolyMPC-DOX conjugates was then assessed in an orthotopic murine breast cancer model. The treatment group given PolyMPC-DOX exhibited a two-fold increase in overall survival and a significant reduction in average tumor volume compared to the free DOX and saline control groups. A study evaluating the therapeutic efficacy of PolyMPC-DOX in a human ovarian xenograft tumor model is ongoing.